Be courteous and considerate

Macleods Pharma USA, Inc. (MPUSA). is the US subsidiary of Macleods Pharmaceuticals Limited (MPL) which develops, manufactures, and globally distributes a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, metered dose inhalers and dry powder inhalers.

In some companies, C-suite executives can be perceived as unapproachable, cutthroat, or even ruthless, but Paul has reinvented company leadership. He recognizes the value of constructive criticism and uses it in his work to solicit feedback from colleagues and peers. Paul is very approachable, easy-to-talk-to, up-to-date on the sector and savvy. He's open, accessible, and team-oriented. He's not only the leader but also part of Macleod's team. Paul is the first to admit when he doesn’t know something. He has an abundance of knowledge but appreciates any opportunity to learn and grow.

As a successful leader, Paul has worked in a wide variety of company cultures…from absolute dictatorships to collaborative team environments. In his career growth, he discovered his leadership priorities by showing his employees that hard work, a willingness to learn, and a ‘can do’ attitude pays off. Paul puts the interests of his employees ahead of his own by providing an opportunity to learn and thrive in a team-based work atmosphere that translates to the overall customer experience. Paul ensures his team’s careers aren't just discussed during annual reviews; rather, he's clear about his expectations and employee’s opportunities for growth. The strength of the company is based on the success of the team that built it!

Paul supports underdogs and fresh business approaches. In a sector that has continued to consolidate into a handful of large buying groups, he wants to continue to diversify MPUSA’s clientele to provide more access of its products to patients in the US. This approach with smaller customers may not materially affect revenue, but it aids in keeping generic drugs affordable and accessible, says Paul. While explaining about MPUSA, Paul asserts that it continues to be the definition of a lean organization. The parent firm oversees several functions to support the US market.

When it comes to competition, according to Paul, the generic drug market is very competitive and puts pressure on profitability in heavily genericized product markets.

Transparency is essential to fostering strong customer connections when it comes to reliable supply of product. Issues arise in any business, and it is critical that customers are made aware of them as soon as possible.

Paul noted that the early on lockdowns made it nearly impossible to cross various state and territory borders in its supply chain at the beginning of the COVID-19 pandemic. Within the span of a few weeks/months he established business continuity practices in MPUSA to reduce consumer impact.

Paul says that the progress of an organization is in its team-based approach, continuous process improvement, and ongoing product growth. MPL had no US presence around ten years ago, but it now competes with many of the top generic manufacturers in the US market.

“Generic manufacturers tend to be lumped in with "Big Pharma," meaning people think that we, as manufacturers, have deep pockets and massive budgets yet the vast majority of our products are ‘me-toos’ and have plenty of generic competition driving pricing down”, according to Paul.

The historical economics of the distribution model of generic pharmaceuticals puts a lot of pressure on manufacturers to continue to drive value year after year for its customers. MPL and Paul aspire to minimize that pressure on the manufacturer in order to provide an everyday low-cost, accessible product solution for all patients of generic pharmaceuticals. IE